trimetazidine - synzeal catalouge... · 2019-05-03 · trimetazidine related products are being...
TRANSCRIPT
CAT No
CAS No
MW
:
:
:
:MF
CAT No
CAS No
MW
:
:
:
:MF
CAT No
CAS No
MW
:
:
:
:MF
CAT No
CAS No
MW
:
:
:
:MF
CAT No
CAS No
MW
:
:
:
:MF
CAT No
CAS No
MW
:
:
:
:MF
CAT No
CAS No
MW
:
:
:
:MF
CAT No
CAS No
MW
:
:
:
:MF
CAT No
CAS No
MW
:
:
:
:MF
CAT No
CAS No
MW
:
:
:
:MF
CAT No
CAS No
MW
:
:
:
:MF
CAT No
CAS No
MW
:
:
:
:MF
Trimetazidine
For more information on our products custom synthesis, contact SynZeal today.
[email protected] www.synzeal.com
SZ-T036001
Trimetazidine DiHCl
13171-25-0
C14H22N2O3.2HCl
266.34 2 36.46
SZ-T036002
Trimetazidine EP Impurity A
52146-35-7
C14H22N2O3
266.34
SZ-T036003
Trimetazidine EP Impurity B
1257-19-8
C24H34N2O6
446.55
SZ-T036004
Trimetazidine EP Impurity C
2103-57-3
C10H12O4
196.2
SZ-T036005
Trimetazidine EP Impurity D
71989-96-3
C10H14O4
198.22
SZ-T036006
Trimetazidine EP Impurity E
356083-64-2 (free base)
C14H22N2O3.2HCl
266.34 2 36.46
SZ-T036007
Trimetazidine EP Impurity F
113698-83-2
C14H22N2O3.2HCl
266.34 2 36.46
SZ-T036008
Trimetazidine EP Impurity G
110-85-0
C4H10N2
86.14
SZ-T036009
Trimetazidine EP Impurity H
53531-01-4
C17H26N2O5
338.41
SZ-T036010
Trimetazidine EP Impurity I
53960-20-6
C15H24N2O3.2HCl
280.37 2 36.46
SZ-T036011
Trimetazidine EP Impurity J
879646-17-0
C15H22N2O4.HCl
294.35 36.46
SZ-T036012
Trimetazidine N-Oxide
N/A
C14H22N2O4
282.34
SynZeal Research offers all related impurities which certified COA with all characterization data like IR, Mass, HPLC Trimetazidinepurity,NMR & TGA report. We also provide CMR, DEPT and detailed structurecharacterization report as perrequirements.
related products are being used by major pharmaceutical companies across the globe for their ANDA/DMF filing.Trimetazidine
Trimetazidine is a drug for angina pectoris sold under the brand name Vastarel MR. Trimetazidine is described as the first cytoprotective anti-ischemic agent developed and marketed by Laboratoires Servier (France). Trimetazidine is an anti-ischemic (anti-anginal) metabolic agent, which improves myocardial glucose utilization through inhibition of long-chain 3-ketoacyl CoA thiolase activity, which results in a reduction in fatty acid oxidation and a stimulation of glucose oxidation. High fatty acid oxidation rates are detrimental during ischemia due to an inhibition of glucose oxidation leading to uncoupling of glycolysis and an increase in proton production, which has the potential to accelerate sodium and calcium overload in the heart, which leads to an exacerbation of ischemic injury and decreased cardiac efficiency during reperfusion.